# A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

> **NCT03737851** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 208 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** elezanumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03737851
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-11
- **Primary completion:** 2021-08-09
- **Final completion:** 2021-09-09
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737851, "A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03737851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*